In order for an abstract to be considered for Late-Breaking Abstract status, the First Author must:
- Submit an abstract, excluding Results and Conclusions sections, by the abstract submission deadline (February 1)
- Adhere to the biostatistical guidelines for phase III trials, with the exception of the Results and Conclusions sections
- Describe the type of data that will be submitted by the Late-Breaking Abstract deadline and define the planned statistical methods for analysis. (For example, “Survival data for the two treatment arms will be compared using a log-rank test.”) Please indicate whether the upcoming analysis will be from a final analysis or the results of an interim analysis. In general, ASCO discourages reporting of interim analysis results, unless approved by the study’s Data and Safety Monitoring Committee.
- Indicate the primary clinical endpoint for the analysis and the current duration of follow-up to warrant Late-Breaking Abstract status
- Indicate the date of planned analysis
- Select the “Intent to Submit Late-Breaking Abstract” check box in the Abstract Submitter program
Late-Breaking Abstracts may only be selected for presentation at Oral Abstract Sessions, Poster Discussion Sessions, for online publication only, or rejection.
The final Late-Breaking Abstracts (with updated data) must be submitted by April 2. If an updated abstract with data and analyses is not submitted, the abstract will be automatically rejected.